Determination and Pharmacokinetics of a New Diorganotin(IV) Complex Dibutyldi(4-chlorobenzohydroxamato)tin(IV) in Rat Plasma by a High Performance Liquid Chromatographic Method

Dibutyldi(4-chlorobenzohydroxamato)tin(IV) is a new diorganotin(IV) arylhydroxamate complex with 4-chloro-benzohydroxamic acid as ligand which shows high in vivo and in vitro antitumor activity. A high performance liquid chromatographic (HPLC) method using a Diamonsil ODS column was first validated...

Full description

Saved in:
Bibliographic Details
Published in:Analytical Sciences 2009/05/10, Vol.25(5), pp.699-703
Main Authors: LI, Yunlan, LIU, Jinjie, LI, Yong, LI, Qingshan
Format: Article
Language:English
Subjects:
Analytical Chemistry
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - blood
Antineoplastic Agents - pharmacokinetics
Blood Chemical Analysis - methods
Chemistry
Chromatography, High Pressure Liquid - methods
Female
Linear Models
Male
Organotin Compounds - administration & dosage
Organotin Compounds - blood
Organotin Compounds - pharmacokinetics
Rats
Rats, Wistar
Sensitivity and Specificity
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dibutyldi(4-chlorobenzohydroxamato)tin(IV) is a new diorganotin(IV) arylhydroxamate complex with 4-chloro-benzohydroxamic acid as ligand which shows high in vivo and in vitro antitumor activity. A high performance liquid chromatographic (HPLC) method using a Diamonsil ODS column was first validated in the pharmacokinetic studies in rat plasma. The plasma was deproteinized with methanol that contained acetanilide as the internal standard. The mobile phase was a mixture of methanol and 0.5% trifluoroacetic acid (TFA) in water (30:70) (pH 3.0). The detection wavelength was set at 238 nm. A linear curve over the concentration range 0.1 - 25 µg/ml (r = 0.9992) was obtained. The method was used to determine the concentration-time profiles for dibutyldi(4-chlorobenzohydroxamato)tin(IV) in the plasma after a single intravenous dose of 2, 5, and 12 mg/kg to rats. The pharmacokinetics parameter calculations and modeling were carried out using the 3p97 pharmacokinetics software. A nonlinear pharmacokinetics was found in rats at doses from 2 to 12 mg/kg. The results showed that the concentration-time curves of dibutyldi(4-chlorobenzohydroxamato)-tin(IV) in rat plasma could be fitted to two-compartment model.
ISSN:0910-6340
1348-2246
DOI:10.2116/analsci.25.699